Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net loss	$ (4,258,279)	$ (4,723,663)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	851,471	946,262
Amortization of held-to-maturity securities, net	(52,037)	(47,516)
Amortization of debt issuance costs	43,961	0
Gain from the sale of investment in Alphazyme	(60,977)	(1,017,592)
Foreign currency exchange loss, net	14,044	38,143
Changes in operating assets and liabilities:
Interest receivable	(30,752)	48,463
Accounts receivable	114,814	(107,666)
Prepaid expenses and other current assets	(46,386)	(91,537)
Operating lease assets and liabilities	1,163	(4,946)
Accounts payable	(109,426)	(691,471)
Accrued expenses	121,623	7,347
Deferred research and development obligation	24,370	(132,353)
Deferred license revenue	0	(26,846)
Net cash used in operating activities	(3,278,411)	(5,803,375)
Cash flows from investing activities
Purchases of held-to-maturity investment securities	(5,971,505)	(2,251,018)
Proceeds from maturities of investment securities	2,771,000	8,373,000
Proceeds from the sale of investment in Alphazyme	60,977	1,293,760
Net cash (used in) provided by investing activities	(3,139,528)	7,415,742
Cash flows from financing activities
Net cash provided by financing activities	5,824,326	0
Effect of exchange rate changes on cash	199	(3,463)
Net (decrease) increase in cash and cash equivalents	(593,414)	1,608,904
Cash and cash equivalents at beginning of period	6,515,028	5,794,272
Cash and cash equivalents at end of period	5,921,614	7,403,176
Supplemental cash flow information
Vesting of restricted stock units	664,086	342,186
Conversion of convertible notes	600,000	0
Cash paid for interest	149,778	0
Right-of-use asset obtained in exchange for lease obligations	0	156,983
Nonrelated Party [Member]
Changes in operating assets and liabilities:
Accrued interest	80,000	0
Cash flows from financing activities
Proceeds from issuance of convertible notes, net of issuance costs	3,882,884	0
Related Party [Member]
Changes in operating assets and liabilities:
Accrued interest	28,000	0
Cash flows from financing activities
Proceeds from issuance of convertible notes, net of issuance costs	$ 1,941,442	$ 0